{
    "organizations": [],
    "uuid": "b9f4ec95ad35d2b7cd34eaba3da3e33cfa6a8c60",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-revance-reports-qtrly-loss-per-sha/brief-revance-reports-qtrly-loss-per-share-0-97-idUSASC0A0MC",
    "ord_in_thread": 0,
    "title": "BRIEF-Revance Reports Qtrly Loss Per Share $0.97",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Revance Therapeutics Inc:\n* QTRLY LOSS PER SHARE $0.97 * REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T04:55:00.000+03:00",
    "crawled": "2018-05-09T12:21:40.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "revance",
        "therapeutic",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "reiterates",
        "financial",
        "guidance",
        "provided",
        "january",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}